Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891446 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT03891446: Active Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by AbbVie.
NCT03891446 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 455 participants, above the 270-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03891446, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
Primary Outcome
Retreatment or rescue administered for IOP lowering, determined by the investigator.
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Bimatoprost SR
Study Locations (20)
California
- Angeles Eye Institute /ID# 250397 - Culver City
- Duplicate_Lakeside Vision Center /ID# 240204 - Irvine
- Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240196 - La Jolla
- The Eye Research Foundation /ID# 240186 - Newport Beach
- North Bay Eye Associates Inc. /ID# 248912 - Petaluma
- Duplicate_Martel Eye Medical Group /ID# 240291 - Rancho Cordova
- The Clinical Trials Network (CTNx) /ID# 240284 - Redding
- Sacramento Eye Consultants /ID# 240263 - Sacramento
- Pacific Eye Associates /ID# 240234 - San Francisco
- Wolstan & Goldberg Eye Associates /ID# 240221 - Torrance
Arizona
- Arizona Eye Center - West Ray Road /ID# 240239 - Chandler
- Arizona Glaucoma Specialists /ID# 240212 - Phoenix
- M&M Eye Institute /ID# 240236 - Prescott
- Horizon Eye Specialists & Lasik Centers /ID# 240255 - Sun City
Florida
- Specialty Retina Center /ID# 240254 - Coral Springs
- Nature Coast Clinical Research - Crystal River /ID# 240334 - Crystal River
- Bruce Segal, MD /ID# 240292 - Delray Beach
- Eye Associates of Fort Meyers /ID# 240218 - Fort Myers
Alabama
- Trinity Research Group /ID# 240190 - Dothan
Colorado
- Colorado Eye Institute /ID# 248910 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What the registry record for NCT03891446 still lists
NCT03891446 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, above the 270-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (69% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT03891446 names 20 study sites across 5 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03891446 about?
NCT03891446 is a clinical study titled "Long-term Safety and Efficacy Extension Trial of Bimatoprost SR". This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercia...
What is the current status of trial NCT03891446?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2019-03-27. Estimated completion is 2026-08.
What conditions does trial NCT03891446 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT03891446?
The interventions under investigation include: Standard of Care (OTHER), Bimatoprost SR (DRUG).
Who is sponsoring clinical trial NCT03891446?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03891446 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03891446's enrollment target sits among peer trials
455 13th of 54 higher than 42 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI